Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis

BACKGROUND: FOLFIRINOX, used in metastatic pancreatic cancer (MPC), is highly efficacious but also toxic. Various dose modifications for FOLFIRINOX have been introduced to reduce toxicity. However, these studies lack a unified pattern for ‘planned’ dose modification, and the ‘actually administered’...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Kwangrok, Choi, Suhyun, Song, Hyunjoo, Kwak, Kyuhan, Anh, Soyeon, Jung, Jae Hyup, Kim, Bomi, Ahn, Jinwoo, Kim, Jaihwan, Hwang, Jin-Hyeok, Lee, Jong-chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333643/
https://www.ncbi.nlm.nih.gov/pubmed/37441327
http://dx.doi.org/10.1177/17588359231175441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333643/
https://www.ncbi.nlm.nih.gov/pubmed/37441327
http://dx.doi.org/10.1177/17588359231175441

Ejemplares similares